{"id":"allisartan-isoproxil-sustained-release-indapamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL406","moleculeType":"Small molecule","molecularWeight":"365.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Allisartan isoproxil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels and promoting sodium retention. Sustained-release indapamide is a thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, promoting sodium and water excretion. Together, these complementary mechanisms provide synergistic antihypertensive effects.","oneSentence":"This combination drug lowers blood pressure by blocking angiotensin II receptors (allisartan isoproxil) and inhibiting sodium reabsorption in the kidney (sustained-release indapamide).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:50.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06500689","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":"Essential Hypertension","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Allisartan Isoproxil/Sustained-Release Indapamide","genericName":"Allisartan Isoproxil/Sustained-Release Indapamide","companyName":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","companyId":"shenzhen-salubris-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers blood pressure by blocking angiotensin II receptors (allisartan isoproxil) and inhibiting sodium reabsorption in the kidney (sustained-release indapamide). Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}